tetano
Editor, Senior Moderator
Cell Rep Med
. 2023 Oct 31:101267.
doi: 10.1016/j.xcrm.2023.101267. Online ahead of print. SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes
Steven C Wall[SUP] 1 [/SUP], Naveenchandra Suryadevara[SUP] 2 [/SUP], Changil Kim[SUP] 3 [/SUP], Andrea R Shiakolas[SUP] 1 [/SUP], Clinton M Holt[SUP] 4 [/SUP], Emma B Irbe[SUP] 2 [/SUP], Perry T Wasdin[SUP] 4 [/SUP], Yukthi P Suresh[SUP] 2 [/SUP], Elad Binshtein[SUP] 2 [/SUP], Elaine C Chen[SUP] 1 [/SUP], Seth J Zost[SUP] 1 [/SUP], Elizabeth Canfield[SUP] 5 [/SUP], James E Crowe Jr[SUP] 6 [/SUP], Mary Ann Thompson-Arildsen[SUP] 5 [/SUP], Daniel J Sheward[SUP] 3 [/SUP], Robert H Carnahan[SUP] 7 [/SUP], Ivelin S Georgiev[SUP] 8 [/SUP]
Affiliations
From the beginning of the COVID-19 pandemic, children have exhibited different susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, reinfection, and disease compared with adults. Motivated by the established significance of SARS-CoV-2-neutralizing antibodies in adults, here we characterize SARS-CoV-2-specific antibody repertoires in a young cohort of individuals aged from 5 months to 18 years old. Our results show that neutralizing antibodies in children possess similar genetic features compared to antibodies identified in adults, with multiple antibodies from children belonging to previously established public antibody clonotypes in adults. Notably, antibodies from children show potent neutralization of circulating SARS-CoV-2 variants that have cumulatively resulted in resistance to virtually all approved monoclonal antibody therapeutics. Our results show that children can rely on similar SARS-CoV-2 antibody neutralization mechanisms compared to adults and are an underutilized source for the discovery of effective antibody therapeutics to counteract the ever-evolving pandemic.
Keywords: B cells; SARS-CoV-2; antibodies; children; infection; neutralization; public clonotype; virus.
. 2023 Oct 31:101267.
doi: 10.1016/j.xcrm.2023.101267. Online ahead of print. SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes
Steven C Wall[SUP] 1 [/SUP], Naveenchandra Suryadevara[SUP] 2 [/SUP], Changil Kim[SUP] 3 [/SUP], Andrea R Shiakolas[SUP] 1 [/SUP], Clinton M Holt[SUP] 4 [/SUP], Emma B Irbe[SUP] 2 [/SUP], Perry T Wasdin[SUP] 4 [/SUP], Yukthi P Suresh[SUP] 2 [/SUP], Elad Binshtein[SUP] 2 [/SUP], Elaine C Chen[SUP] 1 [/SUP], Seth J Zost[SUP] 1 [/SUP], Elizabeth Canfield[SUP] 5 [/SUP], James E Crowe Jr[SUP] 6 [/SUP], Mary Ann Thompson-Arildsen[SUP] 5 [/SUP], Daniel J Sheward[SUP] 3 [/SUP], Robert H Carnahan[SUP] 7 [/SUP], Ivelin S Georgiev[SUP] 8 [/SUP]
Affiliations
- PMID: 37935199
- DOI: 10.1016/j.xcrm.2023.101267
From the beginning of the COVID-19 pandemic, children have exhibited different susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, reinfection, and disease compared with adults. Motivated by the established significance of SARS-CoV-2-neutralizing antibodies in adults, here we characterize SARS-CoV-2-specific antibody repertoires in a young cohort of individuals aged from 5 months to 18 years old. Our results show that neutralizing antibodies in children possess similar genetic features compared to antibodies identified in adults, with multiple antibodies from children belonging to previously established public antibody clonotypes in adults. Notably, antibodies from children show potent neutralization of circulating SARS-CoV-2 variants that have cumulatively resulted in resistance to virtually all approved monoclonal antibody therapeutics. Our results show that children can rely on similar SARS-CoV-2 antibody neutralization mechanisms compared to adults and are an underutilized source for the discovery of effective antibody therapeutics to counteract the ever-evolving pandemic.
Keywords: B cells; SARS-CoV-2; antibodies; children; infection; neutralization; public clonotype; virus.